150 related articles for article (PubMed ID: 37634492)
41. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
[TBL] [Abstract][Full Text] [Related]
42. Castleman Disease: A Multicenter Case Series from Turkey.
Gündüz E; Kırkızlar HO; Ümit EG; Karaman Gülsaran S; Özkocaman V; Özkalemkaş F; Candar Ö; Elverdi T; Küçükyurt S; Paydaş S; Çeneli Ö; Karakuş S; Maral S; Ekinci Ö; İpek Y; Kis C; Güven ZT; Akdeniz A; Celkan T; Eroğlu Küçükdiler AH; Akgün Çağlıyan G; Özçelik Şengöz C; Karataş A; Bulduk T; Özcan A; Belen Apak FB; Canbolat A; Kartal İ; Ören H; Töret E; Özdemir GN; Bakanay Öztürk ŞM
Turk J Haematol; 2022 Jun; 39(2):130-135. PubMed ID: 35176839
[TBL] [Abstract][Full Text] [Related]
43. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA
BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
[TBL] [Abstract][Full Text] [Related]
44. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
45. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
van Rhee F; Rossi JF; Simpson D; Fosså A; Dispenzieri A; Kuruvilla J; Goh YT; Cho SG; Capra M; Liu T; Casper C; Cavet J; Wong RS
Br J Haematol; 2021 Jan; 192(1):e28-e31. PubMed ID: 33128769
[No Abstract] [Full Text] [Related]
46. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
[TBL] [Abstract][Full Text] [Related]
48. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
Milota T; Střížová Z; Sobotková M; Bartůňková J
Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
50. Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
Ha G; Kwong K; Tanaka B; Nishimura Y; Chong C
Eur J Case Rep Intern Med; 2023; 10(7):003904. PubMed ID: 37455698
[TBL] [Abstract][Full Text] [Related]
51. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
Nagao A; Nakazawa S; Hanabusa H
J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
[TBL] [Abstract][Full Text] [Related]
52. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
[TBL] [Abstract][Full Text] [Related]
53. Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.
Basnayake BMDB; Wazil AWM; Kannangara T; Ratnatunga NVI; Hewamana S; Ameer AM
J Med Case Rep; 2017 May; 11(1):135. PubMed ID: 28501028
[TBL] [Abstract][Full Text] [Related]
54. Siltuximab: first global approval.
Markham A; Patel T
Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
[TBL] [Abstract][Full Text] [Related]
55. Clinical development of siltuximab.
Davis CC; Shah KS; Lechowicz MJ
Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
[TBL] [Abstract][Full Text] [Related]
56. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
Lee JP; Kim DK; Oh DY; Paik JH; Moon KC; Kim S; Kim YS
Clin Nephrol; 2011 Feb; 75(2):165-70. PubMed ID: 21255547
[TBL] [Abstract][Full Text] [Related]
57. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
Sugawara E; Sato T; Amasaki Y; Katsumata K
Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301
[TBL] [Abstract][Full Text] [Related]
58. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
Song SN; Tomosugi N; Kawabata H; Ishikawa T; Nishikawa T; Yoshizaki K
Blood; 2010 Nov; 116(18):3627-34. PubMed ID: 20644113
[TBL] [Abstract][Full Text] [Related]
59. Five biopsies, one diagnosis: challenges in idiopathic multicentric Castleman disease.
Semenchuk J; Merchant A; Sakhdari A; Kukreti V
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33229481
[TBL] [Abstract][Full Text] [Related]
60. An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, who Responded well to Rituximab Alone.
Kounatidis D; Rontogianni D; Sampaziotis D; Vardaka M; Giatra C; Dolapsakis C; Margellou E; Vallianou NG
Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):84-86. PubMed ID: 30827270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
